January 4, 2013
Announcing our new National Sales Manager in US for
Uniferon® Mr. Jimmy Heisel.
Uniferon was introduced in the US in 2011 and it has become a
world leading Iron Injectable product for piglets. It is the goal
of Pharmacosmos to establish a stronger market position in US for
Uniferon® in 2013 and in the years to come.
Pharmacosmos is excited to announce that Mr. Jimmy Heisel will
be joining our US team at Pharmacosmos Inc., New Jersey, as
National Sales Manager for Uniferon starting January 1,
2013.
Jimmy comes from a successful position as Senior Sales
Representative at Abbott Animal Health, a division of Abbott
Laboratories. He has expertise in product marketing with strong
commitment of enforcing Uniferon's US market position and
generating sustained, profitable sales growth of the product.
We believe these skills will make Jimmy a valuable addition
to our team
Pharmacosmos' collaboration with partner accounts,
and Ivesco as preferred distribution partner, has generated
impressive results. It is Jimmy's role to establish and
retain long-term relationships with partners, swine producers and
veterinarians. He will also focus his efforts on facilitating
information on best quality procedures on Anaemia Management as
practiced by globally leading swine producers and
veterinarians.
Pharmacosmos looks forward to strengthen its US operations with
the addition of Jimmy Heisel as the National Sales Manager.
The transition and integration of a full-time Sales Manager will
reinforce our commitment to top-notch customer service and
awareness on the importance of Uniferon in the Swine Industry.
Mr. Arnold Baker, our US Business Consultant, has been a
tremendous asset on the introduction and marketing of Uniferon in
the US. We thank him for his efforts and direction.
"We look forward to welcoming Jimmy as a pivotal part of our
global Uniferon team. We see Jimmy's joining our company as a
natural next step in our penetration of the US market said Jens
Fabricius, Vice President, Marketing & Business Operations at
Pharmacosmos A/S".
"Uniferon has undoubtedly experienced a most remarkable and
impressive entry onto the US market and Uniferon is today top of
shelf almost anywhere. My vow is to expand this position and make
Uniferon top of mind as well, enforcing the brand's position in
order to generate additional sales," said Jimmy Heisel.
"I look forward to expand nationwide personal service and
support direct to swine producers and veterinary clinics in the
area of Anaemia Disease Management," said Jimmy Heisel.
Pharmacosmos is dedicated to developing and marketing leading
iron deficiency treatments for both humans and animals. The company
focuses on researching and improving treatment options by building
on industry best practices. Pharmacosmos has an extensive network
of partners in more than 50 countries across Europe, the Americas
and Asia.
Thank you for welcoming Mr. Jimmy Heisel.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.